EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Synergistic antifungal activity of antiretrovirals with amphotericin B against Aspergillus species

Ammar A Khan iD, Ehab A Salama, Mohamed N Seleem iD

PLOS One · 25.03.2026 · 21 (3) · e0344286

DOI: 10.1371/journal.pone.0344286 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, online erschienen am 25.03.2026. Verfasst von Ammar A Khan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Virginia Polytechnic Institute and State Univer…. Hauptthemen laut MEDLINE: Amphotericin B, Antifungal Agents, Aspergillus, Anti-Retroviral Agents. Die Arbeit nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aspergillosis is a life-threatening fungal infection that primarily affects the lungs of immunocompromised individuals, including those living with human immunodeficiency virus (HIV), and is associated with mortality rates exceeding 50%. The infection is predominantly caused by Aspergillus fumigatus , a pathogen that has become increasingly difficult to treat due to the emergence of azole-resistant strains. Although azoles have traditionally served as first-line antifungals, the rise in resistance has necessitated broader use of amphotericin B (AmB), a polyene agent whose clinical utility is limited by its considerable toxicity. To address this therapeutic challenge, we screened a library of 618 antiviral compounds to identify agents that could synergize with AmB and enhance its antifungal efficacy. An initial screen identified 18 compounds that enhanced the antifungal activity of AmB. From this hit set, we prioritized the two FDA-approved HIV drugs, cobicistat and elvitegravir, as promising lead candidates. When combined with AmB, both compounds exhibited potent synergistic activity against A. fumigatus and other clinically relevant Aspergillus species, with FICI values

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amphotericin BAntifungal AgentsAspergillusAnti-Retroviral AgentsDrug SynergismMicrobial Sensitivity TestsHumansAspergillus fumigatusAspergillosis

Substanzen

Amphotericin BAntifungal AgentsAnti-Retroviral Agents

Autor:innen und Institutionen

  • Department of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Virginia Polytechnic Institute and State University, Blacksburg, Virginia, United States of America.
  • Center for One Health Research, Virginia Polytechnic Institute and State University, Blacksburg, Virginia, United States of America.

ORCID-Profile: Ammar A Khan, Mohamed N Seleem

Förderung

  • National Institutes of Health

Zitieren

APA

Khan, A. A., Salama, E. A., & Seleem, M. N. (2026). Synergistic antifungal activity of antiretrovirals with amphotericin B against Aspergillus species. PLOS One, 21(3), e0344286. https://doi.org/10.1371/journal.pone.0344286

Vancouver

Khan AA, Salama EA, Seleem MN. Synergistic antifungal activity of antiretrovirals with amphotericin B against Aspergillus species. PLOS One. 2026;21(3):e0344286. doi:10.1371/journal.pone.0344286

BibTeX
@article{Khan2026,
  author = {Khan, Ammar A and Salama, Ehab A and Seleem, Mohamed N},
  title = {Synergistic antifungal activity of antiretrovirals with amphotericin B against Aspergillus species},
  journal = {PLOS One},
  year = {2026},
  volume = {21},
  number = {3},
  pages = {e0344286},
  doi = {10.1371/journal.pone.0344286}
}
Kostenlos starten →